The Aspirin for the Prevention of Recurrent Venous Thromboembolism ( the Warfarin and Aspirin [ WARFASA ] ) and the Aspirin to Prevent Recurrent Venous Thromboembolism ( ASPIRE ) trials showed that aspirin reduces this risk , but they were not individually powered to detect treatment effects for particular outcomes or subgroups .